Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight is a commercial-stage medical technology company with a unique and innovative intraocular lens technology that allows for customized vision correction after cataract surgery. The recent collaboration with ALC has the potential to generate significant revenue through upfront and milestone payments, as well as royalties on future product sales. Despite current disappointing underlying trends, RxSight is well-positioned for growth in the second half of 2026, driven by increasing utilization and the potential for improved margins. However, the company's success will depend on its ability to effectively commercialize its products and remain competitive in the IOL market.

Bears say

RxSight is a medical technology company with an adjustable intraocular lens (IOL) product that targets patients undergoing cataract surgery. While the company's recent financials show strong gross margin and revenue beat, the high operating expenses and potential risks such as limited adoption and increased competition in the market makes it difficult to see sustained growth and profitability in the long term.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.